Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats

Juan Kong, Gene H. Kim, Minjie Wei, Tao Sun, George Li, Shu Qian Liu, Xinmin Li, Ishir Bhan, Qun Zhao, Ravi Thadhani*, Yan Chun Li

*Corresponding author for this work

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Vitamin D inhibits renin expression and blocks the compensatory induction of renin associated with the use of renin-angiotensin system inhibitors. Here we test the therapeutic effects of two commonly used vitamin D analogs and their combination with losartan on the development of left ventricular hypertrophy. One-month-old male spontaneously hypertensive rats were treated with vehicle, losartan, paricalcitol, doxercalciferol, a combination of losartan and paricalcitol, or a combination of losartan and doxercalciferol for 2 months. Blood pressure was markedly reduced by losartan, but not by paricalcitol or doxercalciferol alone. Echocardiograpy demonstrated a 65 to 80% reduction in left ventricular wall thickness with losartan, paricalcitol, or doxercalciferol monotherapy and almost complete prevention of left ventricular hypertrophy with the combination therapies. Attenuation of cardiac and cardiomyocyte hypertrophy, and suppression of atrial and brain natriuretic peptides, were most marked in the combination therapy groups. These changes were well correlated with left ventricular gene and microRNA expression profiles in the different treatment groups. Renal and cardiac renin expression was markedly increased in losartan-treated animals, but nearly normalized with combination therapy. The same vitamin D analogs suppressed plasma renin activity in patients receiving chronic hemodialysis. These data demonstrate that vitamin D analogs have potent antihypertrophic activity in part via suppression of renin in the kidney and heart, and combination of these analogs with losartan achieves much better therapeutic effects because of the blockade of the compensatory renin increase.

Original languageEnglish (US)
Pages (from-to)622-631
Number of pages10
JournalAmerican Journal of Pathology
Volume177
Issue number2
DOIs
StatePublished - Jan 1 2010

Fingerprint

Losartan
Cardiomegaly
Therapeutic Uses
Inbred SHR Rats
Vitamin D
Renin
Left Ventricular Hypertrophy
Kidney
Brain Natriuretic Peptide
Atrial Natriuretic Factor
Renin-Angiotensin System
Group Psychotherapy
MicroRNAs
Transcriptome
Cardiac Myocytes
Renal Dialysis
Therapeutics
Blood Pressure
1 alpha-hydroxyergocalciferol
paricalcitol

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Kong, Juan ; Kim, Gene H. ; Wei, Minjie ; Sun, Tao ; Li, George ; Liu, Shu Qian ; Li, Xinmin ; Bhan, Ishir ; Zhao, Qun ; Thadhani, Ravi ; Li, Yan Chun. / Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. In: American Journal of Pathology. 2010 ; Vol. 177, No. 2. pp. 622-631.
@article{209c2ad304e24f3093e39434f720b976,
title = "Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats",
abstract = "Vitamin D inhibits renin expression and blocks the compensatory induction of renin associated with the use of renin-angiotensin system inhibitors. Here we test the therapeutic effects of two commonly used vitamin D analogs and their combination with losartan on the development of left ventricular hypertrophy. One-month-old male spontaneously hypertensive rats were treated with vehicle, losartan, paricalcitol, doxercalciferol, a combination of losartan and paricalcitol, or a combination of losartan and doxercalciferol for 2 months. Blood pressure was markedly reduced by losartan, but not by paricalcitol or doxercalciferol alone. Echocardiograpy demonstrated a 65 to 80{\%} reduction in left ventricular wall thickness with losartan, paricalcitol, or doxercalciferol monotherapy and almost complete prevention of left ventricular hypertrophy with the combination therapies. Attenuation of cardiac and cardiomyocyte hypertrophy, and suppression of atrial and brain natriuretic peptides, were most marked in the combination therapy groups. These changes were well correlated with left ventricular gene and microRNA expression profiles in the different treatment groups. Renal and cardiac renin expression was markedly increased in losartan-treated animals, but nearly normalized with combination therapy. The same vitamin D analogs suppressed plasma renin activity in patients receiving chronic hemodialysis. These data demonstrate that vitamin D analogs have potent antihypertrophic activity in part via suppression of renin in the kidney and heart, and combination of these analogs with losartan achieves much better therapeutic effects because of the blockade of the compensatory renin increase.",
author = "Juan Kong and Kim, {Gene H.} and Minjie Wei and Tao Sun and George Li and Liu, {Shu Qian} and Xinmin Li and Ishir Bhan and Qun Zhao and Ravi Thadhani and Li, {Yan Chun}",
year = "2010",
month = "1",
day = "1",
doi = "10.2353/ajpath.2010.091292",
language = "English (US)",
volume = "177",
pages = "622--631",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "2",

}

Kong, J, Kim, GH, Wei, M, Sun, T, Li, G, Liu, SQ, Li, X, Bhan, I, Zhao, Q, Thadhani, R & Li, YC 2010, 'Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats', American Journal of Pathology, vol. 177, no. 2, pp. 622-631. https://doi.org/10.2353/ajpath.2010.091292

Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. / Kong, Juan; Kim, Gene H.; Wei, Minjie; Sun, Tao; Li, George; Liu, Shu Qian; Li, Xinmin; Bhan, Ishir; Zhao, Qun; Thadhani, Ravi; Li, Yan Chun.

In: American Journal of Pathology, Vol. 177, No. 2, 01.01.2010, p. 622-631.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats

AU - Kong, Juan

AU - Kim, Gene H.

AU - Wei, Minjie

AU - Sun, Tao

AU - Li, George

AU - Liu, Shu Qian

AU - Li, Xinmin

AU - Bhan, Ishir

AU - Zhao, Qun

AU - Thadhani, Ravi

AU - Li, Yan Chun

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Vitamin D inhibits renin expression and blocks the compensatory induction of renin associated with the use of renin-angiotensin system inhibitors. Here we test the therapeutic effects of two commonly used vitamin D analogs and their combination with losartan on the development of left ventricular hypertrophy. One-month-old male spontaneously hypertensive rats were treated with vehicle, losartan, paricalcitol, doxercalciferol, a combination of losartan and paricalcitol, or a combination of losartan and doxercalciferol for 2 months. Blood pressure was markedly reduced by losartan, but not by paricalcitol or doxercalciferol alone. Echocardiograpy demonstrated a 65 to 80% reduction in left ventricular wall thickness with losartan, paricalcitol, or doxercalciferol monotherapy and almost complete prevention of left ventricular hypertrophy with the combination therapies. Attenuation of cardiac and cardiomyocyte hypertrophy, and suppression of atrial and brain natriuretic peptides, were most marked in the combination therapy groups. These changes were well correlated with left ventricular gene and microRNA expression profiles in the different treatment groups. Renal and cardiac renin expression was markedly increased in losartan-treated animals, but nearly normalized with combination therapy. The same vitamin D analogs suppressed plasma renin activity in patients receiving chronic hemodialysis. These data demonstrate that vitamin D analogs have potent antihypertrophic activity in part via suppression of renin in the kidney and heart, and combination of these analogs with losartan achieves much better therapeutic effects because of the blockade of the compensatory renin increase.

AB - Vitamin D inhibits renin expression and blocks the compensatory induction of renin associated with the use of renin-angiotensin system inhibitors. Here we test the therapeutic effects of two commonly used vitamin D analogs and their combination with losartan on the development of left ventricular hypertrophy. One-month-old male spontaneously hypertensive rats were treated with vehicle, losartan, paricalcitol, doxercalciferol, a combination of losartan and paricalcitol, or a combination of losartan and doxercalciferol for 2 months. Blood pressure was markedly reduced by losartan, but not by paricalcitol or doxercalciferol alone. Echocardiograpy demonstrated a 65 to 80% reduction in left ventricular wall thickness with losartan, paricalcitol, or doxercalciferol monotherapy and almost complete prevention of left ventricular hypertrophy with the combination therapies. Attenuation of cardiac and cardiomyocyte hypertrophy, and suppression of atrial and brain natriuretic peptides, were most marked in the combination therapy groups. These changes were well correlated with left ventricular gene and microRNA expression profiles in the different treatment groups. Renal and cardiac renin expression was markedly increased in losartan-treated animals, but nearly normalized with combination therapy. The same vitamin D analogs suppressed plasma renin activity in patients receiving chronic hemodialysis. These data demonstrate that vitamin D analogs have potent antihypertrophic activity in part via suppression of renin in the kidney and heart, and combination of these analogs with losartan achieves much better therapeutic effects because of the blockade of the compensatory renin increase.

UR - http://www.scopus.com/inward/record.url?scp=77957274083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957274083&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2010.091292

DO - 10.2353/ajpath.2010.091292

M3 - Article

C2 - 20616348

AN - SCOPUS:77957274083

VL - 177

SP - 622

EP - 631

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 2

ER -